BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
|Articles|August 13, 2020
Hiding in Plain Sight: Racism and What You Can Do About It
Author(s)Heidi Anne Duerr, MPH
What can be done about racism? We're so glad you asked.
Advertisement
While racism is not new, the events of 2020 have emphasized the need to recognize and address the ways racism lurks in medicine, psychiatry, and society.
Seven Psychiatrists Against Racism (SPAR), a diverse and passionate group of professionals, have gathered to
Register for this dynamic Webinar on Thursday, August 20th, at 7:00 PM eastern/4:00 PM pacific by registering
Advertisement
Related to this article
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Check out our pipeline updates from October!
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
A systematic review and meta-analysis compares pharmacological agents with nonpharmacologic approaches to identify the most effective interventions for insomnia in peri- and postmenopausal women.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
2
Burnout, Gratitude, and the Value of Staying Current: On the Mind of Gus Alva, MD, DFAPA
3
GLP-1 Receptor Agonists May Reinforce Restriction in Patients With Eating Disorders
4
Psychedelic Trials Reveal Gaps Between Controlled Efficacy and Real-World Readiness
5